Table 1.
Main clinical trials on immunotherapies and epigenetic agents in monotherapies or in combination
|
Clinical trial
|
Phase
|
Drugs
|
Line/setting
|
Cancer type
|
| NCT033834581 | 3 | Nivolumab vs placebo | ADJ | HCC |
| NCT038670841 | 3 | Pembrolizumab vs placebo | ADJ | HCC |
| NCT030623581 | 3 | Pembrolizumab + BSC vs placebo + BSC | ADJ | HCC |
| NCT034127731 | 3 | Tislelizumab vs sorafenib | 1 | HCC |
| NCT037557912 | 3 | Cabozantinib + atezolizumab vs sorafenib | 1 | HCC |
| NCT044870672 | 3 | Atezolizumab + bevacizumab | 1 | HCC |
| NCT043107092 | 2 | Regorafenib + nivolumab | 1 | HCC |
| NCT044433092 | 1-2 | Lenvatinib + camrelizumab | 1 | HCC |
| NCT043932202 | 2 | Nivolumab + bevacizumab | 1 | HCC |
| NCT037789573 | 3 | TACE + durvalumab + bevacizumab | 1 | HCC |
| NCT042461773 | 3 | Lenvatinib + pembrolizumab + TACE | 1 | HCC |
| NCT043401933 | 3 | Nivolumab + ipilimumab + TACE | 1 | HCC |
| NCT042688883 | 2-3 | Nivolumab + TACE/TAE | 1 | HCC |
| NCT034821023 | 2 | Durvalumab + tremelimumab + radiation | 1 | HCC |
| NCT032984514 | 3 | Durvalumab + tremelimumab and durvalumab vs sorafenib | 1 | HCC |
| NCT040396074 | 3 | Nivolumab + ipilimumab vs SOC | 1 | HCC |
| NCT036057065 | 3 | Camrelizumab + FOLFOX4 | 1 | HCC |
| NCT034398915 | 2 | Sorafenib + nivolumab | 1 | HCC |
| NCT032577616 | 1 | Guadecitabine + durvalumab | 2 | Liver, pancreatic, bile duct or gallbladder cancer |
| NCT028160216 | 2 | Azacitidine + pembrolizumab | 1 | Melanoma |
| NCT045412776 | 2 | Tislelizumab + DNMTi +/- chemotherapy | 1 | AML |
| NCT025304636 | 2 | Nivolumab and/or ipilimumab +/- azacitidine | 1/2 | Myelodysplastic Syndrome |
| NCT035523806 | 2 | Entinostat + nivolumab + ipilimumab | 2 | Kidney |
| NCT031799306 | 2 | Entinostat + pembrolizumab | 2 | Lymphoma |
| NCT026976306 | 2 | Pembrolizumab + entinostat | 1 | Metastatic uveal melanoma |
| NCT032502736 | 2 | Entinostat + nivolumab | 2 | Cholangiocarcinoma and pancreatic adenocarcinoma |
| NCT029155236 | 1/2 | Avelumab +/- entinostat | 1/2 | Ovarian cancer |
| NCT038380426 | 1/2 | Nivolumab + entinostat | 1/2 | CNS, solid tumors |
| NCT030244376 | 1/2 | Atezolizumab with entinostat and bevacizumab | 1/2 | Kidney |
| NCT019285766 | 2 | Nivolumab +/- entinostat + azacitidine | 2 | NSCLC |
| NCT029018996 | 2 | Guadecitabine and pembrolizumab | 2 | Ovarian, primary peritoneal, or fallopian tube cancer |
| NCT031799436 | 2 | Atezolizumab + guadecitabine | 2 | Urothelial carcinoma |
| NCT035769636 | 1/2 | Guadecitabine + nivolumab | 2 | Metastatic colorectal cancer |
| NCT033083966 | 1/2 | Durvalumab + guadecitabine | 1/2 | Kidney |
| NCT029353616 | 1/2 | Guadecitabine + atezolizumab | 2 | Myelodysplastic syndrome or chronic myelomonocytic leukemia |
1
Immune checkpoint inhibitor (ICI) monotherapy.
2
Combination ICI with anti-angiogenic agents.
3
Combination ICI with locoregional treatment.
4
ICI combination.
5
Other ICI combinations.
6
ICI + epigenetic drugs.
AML: Acute myeloid leukemia; BSC: Best supportive care; CNS: Central nervous system; HCC: Hepatocellular carcinoma; NSCLC: Non-small-cell lung carcinoma; SOC: Standard of care; TACE: Transarterial chemoembolization; TAE: Transarterial embolization.